Intuitive Surgical (ISRG)
Nasdaq · Sunnyvale, California, USA · Founded 1995 · CEO Dave Rosa
Valuation summary
$192.52 fair value versus $407.24 in the market, a difference of -52.7%. Rated Sell.
| Fair value per share | $192.52 |
| Current share price | $407.24 |
| Upside / downside | -52.7% |
| Bear case | $134.76 |
| Bull case | $275.34 |
| Discount rate (WACC) | 9.2% |
| Terminal growth | 3.00% |
| Market capitalisation | $141B |
| EV / Sales | 11.8x |
About Intuitive Surgical
Founded in 1995 to commercialise robotic surgery research from SRI International. Gary Guthart was CEO from 2010 until July 2025, when Dave Rosa, previously president, succeeded him and Guthart became executive chair. Intuitive makes the da Vinci surgical system — a robotic platform that lets a surgeon operate through small incisions using instruments controlled from a console — and Ion, a robotic catheter for lung biopsy. The business model is razor-and-blade: systems are placed with hospitals, then Intuitive earns recurring revenue on instruments and accessories consumed in every procedure, plus service contracts.
Investment case
- Recurring instrument revenue grows with procedure volume, independent of new system placements.
- Surgeons train on da Vinci during residency, which creates a professional lock-in that competitors cannot buy their way past.
- Enormous installed base of systems already placed, each generating consumable revenue for a decade.
Key risks
- The valuation is very demanding for a medical device company, on any earnings measure.
- Johnson & Johnson's Ottava was cleared by the FDA in July 2026 for ten general-surgery procedures, the first credible soft-tissue challenger in two decades, and Medtronic and several Chinese manufacturers are also launching platforms.
- Hospital capital budgets tighten when credit conditions do, and system placements are the first thing deferred.
Recent developments
- 2026-10-20 · Q3 revenue up 22% to $3.05bn as da Vinci procedures grow about 14% and 546 systems are placed; GAAP EPS hit by a $450m antitrust settlement source
Revenue by segment
| Instruments & Accessories | 61% |
| Systems | 26% |
| Services | 13% |
Five-year forecast
| Revenue | Free cash flow | |
|---|---|---|
| Year 1 | $13.7B | $2.3B |
| Year 2 | $16.2B | $2.7B |
| Year 3 | $18.6B | $3.1B |
| Year 4 | $20.8B | $3.5B |
| Year 5 | $22.8B | $3.8B |
What the street says
Consistently regarded as a top-quality compounder, but the shares fell sharply in 2026 as investors priced in competition from Ottava. The third quarter of 2026 eased some of that concern: revenue grew 22% to $3.05bn, da Vinci procedures rose about 14% and 546 systems were placed, although GAAP earnings carried a $450m antitrust settlement charge.
Comparable companies: ABT · SNY · REGN · EW · IDXX · MDT · VRTX · SYK
Open the interactive model, price chart and sensitivity grid →